MiracleFeet Foot Abduction Brace Sensor Trial
Launched by MIRACLEFEET · Aug 10, 2017
Trial Information
Current as of May 30, 2025
Unknown status
Keywords
ClinConnect Summary
Clubfoot is the most common birth defect affecting 1 in every 750 live births, that is about 200,000 babies each year globally (80% mainly in developing countries). An estimated average 1 million children are currently living with untreated clubfoot. In India every 10 minutes a child is born with clubfoot i.e. over 50,000 children are born with this deformity every year (1 per 500 birth). The Ponseti Method is now recognized as the accepted standard for the medical treatment of clubfoot. The Ponseti Method is ideally suited for the developing world in that it is inexpensive, non-surgical an...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Unilateral or bilateral cases of idiopathic clubfoot in children who have not yet started walking at first presentation, receiving a brace for the first time after successful correction with the Ponseti method of treatment, at the Bai Jerbai Wadia Hospital for Children over a period of 6 months.
- Exclusion Criteria:
- • All children who are already walking at presentation; All children with previous treatment; All children who have used FAB previously; All children treated with surgery other than tenotomy; All children with syndromic or neuropathic cases of clubfoot; All children with atypical clubfoot.
About Miraclefeet
MiracleFeet is a nonprofit organization dedicated to improving the lives of children with clubfoot, a common congenital condition that can lead to lifelong mobility issues if left untreated. Through innovative treatment protocols, community engagement, and partnerships with local healthcare providers, MiracleFeet aims to ensure that children worldwide have access to effective and affordable care. The organization's commitment to research and clinical trials seeks to enhance treatment methodologies and outcomes, ultimately striving to create a future where every child with clubfoot can walk, run, and thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mumbai, Maharashtra, India
Patients applied
Trial Officials
Alaric Aroojis, MD
Principal Investigator
Bai Jerbai Wadia Hospital for Children
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials